02

2025-05

Superior Efficacy Of Clinical Observational Study In Kx-826 In Combination With Minoxidil For The Treatment Of Male Adults With Aga In China Over Minoxidil Monotherapy

Suzhou, 2 May, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that a clinical observational study of KX-826 in combination with minoxidil for the treatment of male adults with AGA in China has reached the primary endpoint.

20

2025-03

Long-Term Safety Phase III Clinical Trial Of KX-826 For The Treatment Of AGA Reached Primary Endpoint

Suzhou, 20 March, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term safety phase III clinical trial of its in-house developed and potential first-in-class KX-826 tincture for the treatment of AGA has obtained top-line results. Results indicated that the Long-term Safety Clinical Trial has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent safety and efficacy.

13

2025-03

Operation Cooperation Agreement In Relation To Overseas Market Of Cosmetics

Suzhou, 12 March, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Suzhou Kintor Pharmaceuticals, Inc. (the “Suzhou Kintor”), a wholly-owned subsidiary of the Company, entered into a brand and sales operation cooperation agreement (the “Operation Cooperation Agreement”) with Hangzhou ToMax Co., Ltd. (杭州涂麥科技有限公司) (the “ToMax”) in relation to a business cooperation (the “Business Cooperation”) in the sales agency, brand operation and market promotion of the Company’s cosmetics including but not limited to anti-hair loss, acne treatment and skin whitening products in the overseas market.

04

2025-03

30

2024-12

First Subject Enrollment In Phase 3 Stage Of KX-826 1.0% For AGA

Suzhou, 30 December, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Company has successfully completed the first subject enrollment recently in the phase III stage (the “Phase III Stage”) pivotal clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of male adult AGA in China.

29

2024-10

KT-939 INCI Name & Expand To Whitening And Freckle-Removing

Suzhou, 29 Oct 2024-Kintor Pharma announced that KT-939 received INCI name and expand to whitening and freckle-removing.

< 1...345...37 > proceed page

Kintor